Drug Interactions between lurasidone and Opana
This report displays the potential drug interactions for the following 2 drugs:
- lurasidone
- Opana (oxymorphone)
Interactions between your drugs
oxyMORphone lurasidone
Applies to: Opana (oxymorphone) and lurasidone
Using narcotic pain or cough medications together with other medications that also cause central nervous system depression can lead to serious side effects including profound sedation, respiratory distress, coma, and even death. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Do not drink alcohol or self-medicate with these medications without your doctor's approval, and do not exceed the doses or frequency and duration of use prescribed by your doctor. Also, because these medications may cause dizziness, drowsiness, difficulty concentrating, and impairment in judgment, reaction speed and motor coordination, you should avoid driving or operating hazardous machinery until you know how they affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food/lifestyle interactions
oxyMORphone food/lifestyle
Applies to: Opana (oxymorphone)
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Consumption of alcohol while taking immediate- or extended-release formulations of oxymorphone may result in high systemic levels of oxymorphone and fatal overdose even in opioid-tolerant patients. Additionally, alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxymorphone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.
ADJUST DOSING INTERVAL: After oral dosing with 40 mg of oxymorphone hydrochloride in healthy volunteers under fasting conditions or with a high-fat meal, the maximum plasma concentration (Cmax) and systemic exposure (AUC) of oxymorphone were increased by approximately 38% in fed subjects compared to fasted subjects.
MANAGEMENT: Patients taking opioid analgesics including oxymorphone should not consume alcohol or use medications that contain alcohol. Modified and/or extended-release oxymorphone formulations must also be swallowed whole and not crushed, chewed or divided. In addition, oxymorphone should be administered on an empty stomach, at least 1 hour before or 2 hours after food intake.
lurasidone food/lifestyle
Applies to: lurasidone
Avoid consuming grapefruit or grapefruit juice during treatment with lurasidone, as it may increase blood levels of the medication. This can increase the risk of side effects such as Parkinson-like symptoms, abnormal muscle movements, seizures, high blood sugar, diabetes, high cholesterol, weight gain, sex hormone irregularities, and heat-related disorders such as heat intolerance or heat stroke. In addition, you may be more likely to experience side effects associated with low blood pressure such as dizziness, lightheadedness, headache, flushing, fainting, and heart palpitations. You should also avoid the use of alcohol while being treated with lurasidone. Alcohol can increase the nervous system and blood-pressure lowering effects of lurasidone. You may experience increased drowsiness, dizziness, difficulty concentrating, and impairment in thinking and judgment. Talk to your doctor or pharmacist if you have any questions or concerns. Lurasidone should be taken with food consisting of at least 350 calories. Avoid driving or operating hazardous machinery until you know how the medication affects you, and use caution when getting up from a sitting or lying position.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.